Christopher C. Gallen

Dr. Gallen trained initially in Philosophy (University of Florida) then trained as a Medical Scientist (M.D., Ph.D., Emory), psychiatrist (Stanford) and neurologist (UCSD) then led an innovative career as an academician (The Scripps Research Institute) where his laboratory with great collaborators pioneered the use of Magnetic Source Imaging developing the first clinical indications for the technology, made important scientific discoveries (including the first demonstration of human cerebral plasticity and of the 40 Hz current in man) and acted as a scientific spokesman supporting the NADAQ IPO of BTi. Dr. Gallen then joined Quintiles, rising to Sr. Medical Director, where he drove pivotal trials of several therapeutics that became registered for CNS and other disorders.

Dr. Gallen then became President of the nascent Premier Research Worldwide (PRWW) and with great staff innovated the first use of Remote Data Capture into the Clinical Research Organization (CRO) field, (an approach now circa >95% of CRO data handling globally), introduced Computer Assisted Research and Development (CARD) into clinical research, played a key role in developing the therapeutic that became XYREMTM led PRWW to become a public company through a NASDAQ IPO then grew the company to international status. Dr. Gallen then joined Pharmacia as VP Medical Research where he led CNS development and/or registration of several therapeutics, managed clinical operations for all therapeutic areas in the Americas, played a leadership role in the successful re-engineering of Pharmacia clinical and was promoted to Site Head R&D for the Kalamazoo site.

Dr. Gallen next became VP Clinical Operations at Wyeth where, enabled by great staff and collaborators, he led a transformative reorganization that produced top tier industry performance, created the Alliance for Clinical Excellence (ACE) with Accenture (the first large scale industry movement into use of India for data management), and developed what emerged as the Functional Services Model for managing out-sourcing, now one of the main industry models globally. Dr. Gallen next became CEO of Vancouver-based Neuromed, negotiated a large collaboration with Merck, in-licensed OROS-hydromorphone from Alza, took Neuromed public becoming CEO of Combinatorx and later, as head of R&D, registered EXALGO™. Prior to joining WEX Pharmaceuticals Inc. as CEO, Dr. Gallen was CEO of SK Biopharmaceuticals, the first Western CEO of a major Korean pharmaceutical company, led its fine staff in significant advancement – moving important therapeutics into successful late stage trials and guided the successful re-focusing of its Custom Manufacturing Business.